Siunpharma looks week in daily chart and seems it can fall 1680 zone as per price support on that area where bulls vcan activate and bears will close their position.
📈 Technical Indicators
Moving Averages: Strong Sell
Technical Indicators: Strong Sell
RSI (14): 31.939 (Approaching oversold territory)
MACD (12,26): -13.57 (Bearish)
ADX (14): 30.04 (Indicates trend strength)
Williams %R: -97.69 (Oversold)
🔍 Demand & Resistance Zones
Demand Zone: ₹1,840–₹1,850
Sellers' Liquidity Zone: ₹1,920
Major Resistance: ₹1,960 (All-time high on Sep 30, 2024)
📌 Trade Setup
Entry: Consider long positions near ₹1,850 or upon breakout above ₹1,860
Targets:
Target 1: ₹1,920
Target 2: ₹1,960
Stop-Loss: Below ₹1,820
Risk-Reward Ratio: Minimum 1:2
🧠 Fundamental Insights
Analyst Consensus: Buy
12-Month Price Target: Average ₹2,051.84 (Upside of ~14.98%)
EPS Growth Forecast: 12.3% per annum
Revenue Growth Forecast: 9.8% per annum
Return on Equity Forecast: 16.9% over 3 years
🧬 Recent Developments
Acquisition: Acquired Checkpoint Therapeutics for $355 million in March 2025, enhancing oncology portfolio
Earnings Beat: Q3 FY25 EPS of ₹13.40 vs. estimate of ₹11.98; Revenue of ₹136.75B vs. estimate of ₹133.98B
📈 Technical Indicators
Moving Averages: Strong Sell
Technical Indicators: Strong Sell
RSI (14): 31.939 (Approaching oversold territory)
MACD (12,26): -13.57 (Bearish)
ADX (14): 30.04 (Indicates trend strength)
Williams %R: -97.69 (Oversold)
🔍 Demand & Resistance Zones
Demand Zone: ₹1,840–₹1,850
Sellers' Liquidity Zone: ₹1,920
Major Resistance: ₹1,960 (All-time high on Sep 30, 2024)
📌 Trade Setup
Entry: Consider long positions near ₹1,850 or upon breakout above ₹1,860
Targets:
Target 1: ₹1,920
Target 2: ₹1,960
Stop-Loss: Below ₹1,820
Risk-Reward Ratio: Minimum 1:2
🧠 Fundamental Insights
Analyst Consensus: Buy
12-Month Price Target: Average ₹2,051.84 (Upside of ~14.98%)
EPS Growth Forecast: 12.3% per annum
Revenue Growth Forecast: 9.8% per annum
Return on Equity Forecast: 16.9% over 3 years
🧬 Recent Developments
Acquisition: Acquired Checkpoint Therapeutics for $355 million in March 2025, enhancing oncology portfolio
Earnings Beat: Q3 FY25 EPS of ₹13.40 vs. estimate of ₹11.98; Revenue of ₹136.75B vs. estimate of ₹133.98B
Trade closed: target reached
Sunpharma low was 1626 target achieved and its 100 point fall. amazing trade.My Educational Telegram channel:
t.me/bullsbearsfight
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
t.me/bullsbearsfight
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
My Educational Telegram channel:
t.me/bullsbearsfight
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
t.me/bullsbearsfight
My YouTube channel: youtube.com/channel/UC537A
My Indicator details:
docs.google.com/document/d/17wUSbSJEZR6rTNVdwqLEBaKM-CSYx-61TN0qazvsnAQ/edit?usp=sharing
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.